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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by hamartomas in
any organ systems. Mutations in the TSC1 or TSC2 gene lead to the dysfunction of hamartin or tuberin proteins,
which cause tuberous sclerosis complex.
Case presentation: We describe the clinical characteristics of patients from a Chinese family with tuberous sclerosis
complex and analyze the functional consequences of their causal genetic mutations. A novel heterozygous mutation
(c.3610G > A) at the last nucleotide of exon 29 in TSC2 was identified. On the protein level, this variant was presumed
to be a missense mutation (p.Gly1204Arg). However, the splicing assay revealed that this mutation also leads to the
whole TSC2 exon 29 skipping, besides the wild-type transcript. The mutated transcript results in an in-frame deletion of
71 amino acids (p.Gly1133_Thr1203del) and its ratio with the normal splice product is of about 44:56.
Conclusions: The novel c.3610G > A TSC2 mutation was identified in association with tuberous sclerosis complex. And
it was proven to code both for a missense-carrying transcript (56%), and for an isoform lacking exon 29 (44%).
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Background
Tuberous Sclerosis Complex (TSC) is a neurocutaneous
disorder with a birth incidence of approximately 1/
6,000–1/10,000, and affecting almost 2 million people
worldwide [1, 2]. It is characterized by the uncontrolled
benign mesenchymal tumor growth in multiple organ
systems, including the brain, skin, heart, lung and kidney
[3, 4]. The spectrum of clinical manifestation is very
wide among individuals due to the different location of
the lesions, with combination of symptoms including
seizures, developmental delay, intellectual disability,
behavioral problems, skin abnormalities, and lung or
kidney disease. The differences between gender and
races of TSC have not been found, and it will appear at
any age ranging from birth to adulthood [5]. TSC is an
autosomal-dominantly inherited disorder with high
penetrance but variable expressivity, regardless of muta-
tions in either TSC1 or TSC2 gene.
TSC1 and TSC2 respectively code for the hamartin
and tuberin proteins, which act as tumor growth suppressors.
Hamartin and tuberin interact with each other through their
coiled-coil domains to form a stable and functional heterodi-
mer that promotes the GTPase activity of Rheb protein, thus
preventing the Rheb-GTP-dependent stimulation of cell pro-
liferation, adhesion, growth, differentiation and migration,
through the mTOR pathway [3, 6–8]. Consistent with the
Knudson ‘two-hit’ tumor-suppressor gene model [9], a first
germline mutation inactivating one allele of either TSC1 or
TSC2, and subsequently a somatic event (often loss of het-
erozygosity) inactivating the second allele, result in
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upregulation of the mTOR pathway and lead to overactive
cell growth and proliferation [10].
So far, 1,478 different mutations in the TSC genes have
been identified to be responsible for the vast majority of
cases of TSC according to HGMD (HGMD Professional
2017.4). Herein, we performed clinical and genetic inves-
tigation in a Chinese family with classical TSC, and re-
ported the novel heterozygous c.3610G > A, p.G1204R
mutation in exon 29 of TSC2 gene, Meanwhile, the ef-
fect of this variant in the splicing process was investi-
gated by a mini-gene assay and the RNA analysis.
Case presentation
The pedigree of the family is shown in Fig. 1. The pro-
band (Ib in Fig. 1) was a 47-year-old female of Han
Chinese ethnicity (with family from Shandong province,
China), who was admitted to our hospital with a chief
complaint of “fatigue and chest tightness for 7 days”. She
never had a similar episode before. She had neither in-
tellectual disability nor a history of seizures. Her blood
pressure was 135/85 mmHg. Physical examination re-
vealed typical facial angiofibromas (adenoma sebaceum)
and multiple periungual fibromas (Fig. 2), and obvious
abdominal distention. Her biochemical laboratory test
demonstrated renal insufficiency (serum creatinine
levels: 3.1 mg/dL, normal values 0.5–1.1 mg/dL; esti-
mated glomerular filtration rate: 17.1 ml/min/1.73 m2,
estimated by CKD-EPI formula) and moderate anemia
(hemoglobin of 8.6 g/dL, normal values 11–15 g/dL).
Ultrasonography of her both kidneys manifested a het-
erogeneous mass with a large echogenic fatty component
and a less echogenic soft-tissue component with prom-
inent vessels within it, which was suggestive of giant bi-
lateral renal angiomyolipomas (AML) (Fig. 3a). Highly
vascular fatty masses were seen on Color Doppler scans
(Fig. 3b). Ultrasonography of the left eyes demonstrated
a hyperechogenic lesion with posterior shadowing due to
calcifications (Fig. 3d). Fundus photograph showed a
hamartoma with central calcifications and a surrounding
translucent zone in the left eye, suggesting the retinal
hamartoma (Fig. 4). Thereafter, non-contrast-enhanced
computed tomography (CT) of the abdomen confirmed
the ultrasonography diagnosis of giant bilateral renal
AMLs with prominent fatty components and internal
prominent vessels. Multiple variable-sized air-filled cysts
throughout the parenchyma were noted in both lungs
consistent with lymphangioleiomyomatosis (LAM) on
lung CT. And brain CT revealed multiple calcified sube-
pendymal nodules. Images of spine displayed multiple
patchy sclerotic lesions (Fig. 5).
Therefore, we considered that the patient fulfilled the
diagnostic criteria of TSC [11]. The patient accepted the
treatment with the mTOR inhibitor everolimus (10 mg/
d) because her AMLs nearly invaded all tissues of bilat-
eral kidneys which could not be removed completely.
Two months later, the patient felt a significant allevi-
ation in the feeling of abdominal swelling. Regrettably,
she had to discontinue her treatment because of finan-
cial difficulties. After half a year follow-up, the patient
remained in a stable condition. Besides, she had a son
(IIc) who died of epilepsy at the age of six. Her daughter
(IIa) also had the presentation of typical facial angiofi-
bromas and multiple periungual fibromas, but she de-
nied further imaging examination. Her husband (Ia) and
granddaughter (IIIa) did not show any significant symp-
toms or abnormalities on testing. To further confirm the
diagnosis of TSC, mutation analysis of the TSC1 and
TSC2 gene and bioinformatics analysis were performed
by the methods in Additional file 1. The CARE guide-
lines were followed in reporting this case.
By the next generation sequencing, the proband was
found to carry a heterozygous guanine to adenine substi-
tution of the last nucleotide in exon 29 of TSC2
(c.3610G > A), resulting in a single amino acid substitution
from Glycine to Arginine at amino acid position 1204
(p.Gly1204Arg) (Fig. 6). Sanger sequencing validation of
all family members revealed that the proband’s daughter
(IIa) carried the same heterozygous p.Gly1204Arg muta-
tion in TSC2 gene, whereas other family members and
Fig. 1 Pedigree of the kindred with Tuberous Sclerosis
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100 unrelated controls did not harbor this mutation. No
mutation was identified in TSC1 gene.
The c.3610G >A variant was considered as novel since
it was neither present in ExAC, 1000G, nor in HGMD da-
tabases (HGMD Professional 2017.4). However, another
substitution at the same codon (c.3611G > A, p.Gly1204-
Glu) has been reported to be related with TSC [12].
The p.Gly1204Arg alteration was predicted as deleteri-
ous by three different softwares (i.e. MutationTaster,
SIFT and PolyPhen-2). Moreover, the p.Gly1204Arg vari-
ant is highly conserved among 8 different species (hu-
man, Callorhinchus milii, Macaca mulatta, chimpanzee,
house mouse, rat, xenopus tropicalis and zebrafish) by
using Vector NTI Advance 10-Align.
It was noteworthy that the c.3610G > A was a nucleo-
tide substitution at the last position of exon 29, which
was located at the upstream close neighbor nucleotide of
classical donor splicing site (GT) of intron 29. Therefore,
this position may play an important role as splicing
modulator. The BDGP and the NetGene2 splice predic-
tion programs were then employed to test whether this
mutation could alter the splicing of the TSC2 transcript.
Both predictions resulted in the abolishment of the
donor splice site. Finally, the in silico analysis by ASSP
software showed that the splice donor site strength re-
markably decreased from a score of 8.434 to 4.895 (cut
off: 4.5).
The mini-gene assay performed to study the effects at
the transcript level of the novel c.3610G > A variant
showed that the wild-type gave rise to a 476 bp PCR
product containing exon 29, the empty pSPL3 control
gave rise to a 263 bp PCR fragment missing exon 29 of
TSC2 gene. However, the c.3610G > A mutant construct
produced two transcripts corresponding to 263 and
476 bp PCR fragments, respectively (Additional file 2:
Figure S1). We then investigated whether the mutation
c.3610G > A really led to exon 29 skipping in an actual
patient. The cDNA was reverse transcribed from total
RNA extracted from peripheral blood leucocytes of the
proband. By cDNA sequencing, the exon 29-excluded
transcript was identified only in the proband and not in
a not-mutated individual. Approximately 44% of the
cDNA products inserted into the pGEMT Easy vector
were missing exon 29, whereas 56% were in-frame
Fig. 2 Clinical photographs of the proband. a. adenoma sebaceum; b, c. subungual fibromas
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cDNA with the single nucleotide change c.3610G > A
(Fig. 7).
Discussion and conclusions
In this investigation, by preliminary mutation analysis of
TSC gene in this family, a novel heterozygous mutation
(c.3610G > A, p.Gly1204Arg) of exon 29 was identified
in the TSC2 gene. Predictions by in silico softwares re-
vealed that it could be pathogenic in both protein and
mRNA levels. On protein level, the substitution of a
small molecular Gly to a more bulky Arg residue at
highly conserved position 1204 strongly suggests that
this missense mutation is pathogenic. On mRNA level,
the results based on the mini-gene splicing assay and the
RNA analysis from peripheral blood leucocytes con-
firmed the deleterious effect of the c.3610G > A alter-
ations on the splicing process, demonstrating that the
last nucleotide (c.3610G) of exon 29 in TSC2 gene is an
important controller of splicing. The change of guanine
to adenine at this position led indeed to a significant de-
crease in the ability of donor splice site recognition.
Above data strongly suggest that the exonic mutation of
Fig. 3 Ultrasonography of both kidneys and eyes of the proband. a, Renal ultrasound image showing a heterogenous mass with a large
echogenic fatty component and a less echogenic soft-tissue component with prominent vessels within it; b, Color doppler ultrasoud image
showing highly vascular fatty masses; c, Right eye; d, Left eye: demonstrating a hyperechogeneic mass (hamartoma) with posterior shadowing
due to calcifications
Fig. 4 Fundus Photograph of the proband Ib. a. Left eye, Fundus photograph of a hamartoma with central calcifications and a surrounding
translucent zone. b. Right eye
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c.3610G > A disturbed the normal splicing. The skipping
of whole exon 29 is predicted to lead to a defective
tuberin with an in-frame deletion of 71 amino acids
from p.Gly1133 to p.Thr1203 (p.Gly1133_Thr1203del),
and a severe impairment of the normal hamartin-tuberin
interaction, thus resulting in an upregulation of the
mTOR pathway and the generation of TSC. Therefore,
with combination of in silico algorithms, in vitro assays
and in vivo analyses, an exonic point mutation, which
may lead to the disease by both an exon skipping form
(accounting for 44%) and a single amino residue alter-
ation (accounting for 56%), was determined in the pa-
tients with TSC.
More than half of missense mutations in human are
estimated to be the trigger for diseases via affecting the
splicing process [13]. For years, only intronic mutations
affecting donor or acceptor splice sites (DS or AS) were
considered to potentially alter transcriptional processing.
This has been questioned as the understanding of spli-
cing mechanisms and concerned splicing signals has
Fig. 5 Non-contrast-enhanced CT Imaging of the proband Ib. a. Lung CT scans showing presence of multiple variable sized air filled cysts
consistent with lymphangiomyomatosis. b. Abdomen CT scans showing massive bilateral predominantly fatty renal masses consistent with
angiomyolipomas. c. Brain CT showing multiple calcified subependymal nodules. d. Spine X-ray showing multiple patchy sclerotic lesions
Fig. 6 TSC2 mutations identified in the proband Ib with TSC
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improved. To our knowledge, the core splicing signals
were constitutive of the three motifs (DS, AS and branch
point sequence BPS). However, it has been elucidated
that the additional signals classified as exonic splicing
enhancers (ESEs) or silencers (ESSs), which can promote
or inhibit the exon recognition, respectively [14, 15]. In
the same way, enhancer (ISE) or silencer (ISS) signals
can also be located within introns. In view of the import-
ance of core and auxiliary splicing signals in the
pre-mRNA splicing process, it is now recognized that all
types of mutations (missense, nonsense as well as small
insertions or deletions) can indeed lead to splicing de-
fects either by disrupting or creating signals [16].
In the present family, the proband was characterized
by multi-systematic impairment and severe phenotypes,
including severe AML of both kidneys, pulmonary LAM
and retinal hamartoma. Her son (IIc), a highly suspicious
TSC patient, died of epilepsy at the age of 6. Thus, con-
sistent with previous study [7, 12, 17, 18], this family
harboring the c.3610G > A TSC2 mutation demonstrated
a relatively severe phenotype. Furthermore, this investi-
gation revealed that there was great phenotype variabil-
ity and different penetrance among TSC patients who
share the same mutation of TSC2 gene. The “two-hit”
hypothesis, loss of heterozygosity (LOH) or biallelic in-
activation caused by a somatic “second-hit” mutation in
the other unaffected TSC1 or TSC2 allele on the basis of
a heterozygous germline mutation, is an important
concept in understanding the variable clinical expres-
sion in TSC. However, it was not possible to confirm
this hypothesis because we cannot obtain the patho-
logical tissue of this patient. Additionally, modifier
genes or other factors may be involved in the pheno-
type variability of TSC. More recently, some investi-
gations revealed that epigenetic changes, including
microRNAs that regulate TSC1 and TSC2 protein ex-
pression, may also contribute to phenotype diversity
in TSC [19].
In this study, a novel TSC2 missense mutation
(c.3610G > A, p.Gly1204Arg), acting both at protein level
as a missense alteration (56% of the transcript), and also
at mRNA level contributing to exon 29 skipping (44% of
the transcript), was identified in a Chinese family with
typical TSC. This finding will further expand the TSC
mutation database and increase the comprehension of
the molecular abnormalities caused by TSC.
Fig. 7 RNA analysis. a Electrophoresis for amplification of TSC2 cDNA in the proband and a normal person. b Sequencing chromatogram of TSC2
cDNA in the proband and a normal person. Upper panel, wild type; Middle panel, transcripts with missense mutation c.3610G > A; Lower panel,
transcripts lacking exon 29. The asterisk indicated the position of mutation (c.3610G > A) of exon 29 in TSC2
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Additional files
Additional file 1: Materials and methods. A detailed description of the
sample acquisition, next generation sequencing (NGS), bioinformatics
analyses, multiplex ligation-dependent probe amplification (MLPA),
Sanger sequencing, mini-gene constructions expression and RNA analysis.
(DOCX 28 kb)
Additional file 2: Figure S1. The mini-gene splicing assay based on the
pSPL3 exon trapping vector. A. The pSPL3 vector contains the two exons,
namely SD and SA, and a functional intron, with transcription beginning
following the SV40 promoter and ending at the LPAS. Wild pSPL3-W and
mutant pSPL3-M plasmids containing 293 bp of intron 28, 213 bp of
exon 29 and 352 bp of intron 29 were separately cloned into the XhoI
and NheI cloning sites of the pSPL3 vector. B. Agarose gel electrophoresis
of RT-PCR products. SD6 and SA2 primers were designed for RT-PCR
amplification of cDNA sequences generated by transfected 293 T cells.
Lane 1: marker; Lane 2: 476 bp (263 + 213 bp); Lane 3: empty vector
(263 bp); Lane 4: 263 and 476 bp (263 bp + 213 bp). MCS =Multiple
cloning sites; LPAS = late poly(A) signal. (TIFF 2397 kb)
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AML: Angiomyolipoma; AS: Acceptor splicing site; BPS: Branch point
sequence; DS: Donor splicing site; ESEs: Exonic splicing enhancers;
ESSs: Exonic splicing silencers; GTPase: Guanosine triphosphatase; ISE: Intronic
splicing enhancer; ISS: Intronic splicing silencer;
LAM: Lymphangioleiomyomatosis; mTORC1: mechanistic target of rapamycin
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